Patricia Kropf

3.3k total citations
26 papers, 341 citations indexed

About

Patricia Kropf is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Patricia Kropf has authored 26 papers receiving a total of 341 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 13 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Patricia Kropf's work include Acute Myeloid Leukemia Research (17 papers), Histone Deacetylase Inhibitors Research (7 papers) and Epigenetics and DNA Methylation (7 papers). Patricia Kropf is often cited by papers focused on Acute Myeloid Leukemia Research (17 papers), Histone Deacetylase Inhibitors Research (7 papers) and Epigenetics and DNA Methylation (7 papers). Patricia Kropf collaborates with scholars based in United States, Canada and Denmark. Patricia Kropf's co-authors include Jean‐Pierre J. Issa, Takahiro Sato, Stefan K. Barta, Hagop M. Kantarjian, Gail J. Roboz, S.B. Hayes, Casey L. O’Connell, Nicholas G. Zaorsky, Nestor F. Esnaola and Joshua E. Meyer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Patricia Kropf

24 papers receiving 333 citations

Peers

Patricia Kropf

HEMAT

GENET

ONCOL

IMMUN

Katharina Lisenko Germany

Vitina Grieco Italy

Naïs Prade France

Danielle Shafer United States

Haerim Chung South Korea

Jennifer D. Morrissette United States

Haytham Khoury Canada

Ulrich Pascheberg Germany

Maho Ishikawa Japan

Marios Dimitriou Sweden

Katharina Lisenko Germany

Patricia Kropf

104 ×0.5

128 ×0.9

HEMAT

52 ×0.7

GENET

77 ×1.3

ONCOL

41 ×0.8

IMMUN

Citations per year, relative to Patricia Kropf Patricia Kropf (= 1×) peers Katharina Lisenko

Countries citing papers authored by Patricia Kropf

Since Specialization

Citations

This map shows the geographic impact of Patricia Kropf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Kropf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Kropf more than expected).

Fields of papers citing papers by Patricia Kropf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia Kropf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Kropf. The network helps show where Patricia Kropf may publish in the future.

Co-authorship network of co-authors of Patricia Kropf

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Kropf. A scholar is included among the top collaborators of Patricia Kropf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Kropf. Patricia Kropf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kropf, Patricia, Woonbok Chung, Lianchun Xiao, et al.. (2025). A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML. PubMed. 2(2). 100071–100071.

Moreb, Jan S., et al.. (2023). The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation. Transfusion and Apheresis Science. 62(6). 103787–103787. 1 indexed citations

Chung, Woonbok, Andrew D. Kelly, Patricia Kropf, et al.. (2019). Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. Clinical Epigenetics. 11(1). 106–106. 20 indexed citations

Redner, Robert L., Jan H. Beumer, Patricia Kropf, et al.. (2018). A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leukemia & lymphoma. 59(11). 2595–2601. 10 indexed citations

Kelly, Andrew D., Jozef Madžo, Priyanka Madireddi, et al.. (2018). Demethylator phenotypes in acute myeloid leukemia. Leukemia. 32(10). 2178–2188. 7 indexed citations

O’Connell, Casey L., et al.. (2018). Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Relapsed or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia. Blood. 132(Supplement 1). 1811–1811. 7 indexed citations

Ogba, Ndiya, Nancy L. Bartlett, Patrick A. Brown, et al.. (2018). Chimeric Antigen Receptor T-Cell Therapy. Journal of the National Comprehensive Cancer Network. 16(9). 1092–1106. 15 indexed citations

Roboz, Gail J., Hagop M. Kantarjian, Karen Yee, et al.. (2017). Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 124(2). 325–334. 49 indexed citations

Sato, Takahiro, Jean‐Pierre J. Issa, & Patricia Kropf. (2017). DNA Hypomethylating Drugs in Cancer Therapy. Cold Spring Harbor Perspectives in Medicine. 7(5). a026948–a026948. 106 indexed citations

10.

Zaorsky, Nicholas G., Stefan K. Barta, Nestor F. Esnaola, et al.. (2016). Splenic irradiation for splenomegaly: A systematic review. Cancer Treatment Reviews. 53. 47–52. 33 indexed citations

11.

Kropf, Patricia, Philip Pancari, Henry C. Fung, et al.. (2016). Improved Survival for MDS/CMML Patients Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC Alone Vs. DAC +/- Carboplatin or ATO. Blood. 128(22). 3170–3170. 1 indexed citations

12.

Hossain, Nasheed, Thomas R. Klumpp, Patricia Kropf, et al.. (2015). Donor Lymphocyte Infusion in Hematologic Malignancies—Good to be Fresh?. Clinical Lymphoma Myeloma & Leukemia. 16(2). 111–115. 6 indexed citations

13.

Kropf, Patricia, et al.. (2015). Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia. Leukemia & lymphoma. 57(4). 935–941. 4 indexed citations

14.

Gottipati, Srikanth, Shashank Rohatagi, Woonbok Chung, et al.. (2015). Multivariate Analysis Identifies Significant Correlations Between Baseline Biomarkers, DNA Demethylation and Clinical Responses in 122 Patients Treated in a Phase 1/2, Study of Guadecitabine (SGI-110), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (r/r AML). Blood. 126(23). 2594–2594. 1 indexed citations

15.

Ravandi, Farhad, Patricia Kropf, Karen Yee, et al.. (2014). Comparison of Efficacy and Safety of 5-Day and 10-Day Schedules of Sgi-110, a Novel Subcutaneous (Sc) Hypomethylating Agent (Hma), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R Aml). Annals of Oncology. 25. iv328–iv328. 1 indexed citations

16.

Griffiths, Elizabeth A., Hagop M. Kantarjian, Gail J. Roboz, et al.. (2014). First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).. Journal of Clinical Oncology. 32(15_suppl). 7030–7030. 5 indexed citations

17.

Patel, Rushang D., Thomas R. Klumpp, Mary Ellen Martin, et al.. (2013). A Retrospective Analysis Of The Association Between Common Myeloablative Conditioning Regimens and Hepatotoxicity. Blood. 122(21). 5515–5515. 1 indexed citations

18.

Chung, Woonbok, Pietro Taverna, John F. Lyons, et al.. (2013). Determinants Of Demethylation and Clinical Response In AML Patients Treated With SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA) In a Phase 1 Study. Blood. 122(21). 1442–1442. 2 indexed citations

19.

Foon, Kenneth A., Suzanne Lentzsch, Patricia Kropf, et al.. (2012). Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood. 119(13). 3184–3185. 34 indexed citations

20.

Klumpp, Thomas R., Kenneth F. Mangan, Mary Ellen Martin, et al.. (2011). Spontaneous graft versus host disease occurring in a patient with multiple myeloma after autologous stem cell transplant. American Journal of Hematology. 87(2). 219–221. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact